Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.
[en] Background Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of skin inflammation. Aim To assess the benefit of topical applications of a new product (P-3075). Patients/Methods A randomized, multicenter, double-blind, placebo-controlled, parallel-group, pilot study was carried out to evaluate the efficacy and tolerability of a cream (P-3075) based on 5% potassium azeloyl diglycinate (PAD, Azeloglicina((R)) ) and 1% hydroxypropyl chitosan (HPCH). Forty-two patients (rosacea stages I and II) were enrolled and randomized, 28 in the P-3075 group and 14 in the placebo group. They were asked to apply the cream twice daily for 4 weeks. The main assessments were the objective quantification of erythema and skin hydration using the Mexameter((R)) and Corneometer((R)) devices, respectively. Clinical signs and symptoms were evaluated on a four-point scale. Results The P-3075 cream applied for 28 days was effective in skin protection by reducing erythema, evaluated both instrumentally and clinically. In addition, the clinical assessments of other symptoms such as flushing, stinging, and burning supported the beneficial effect of the P-3075 cream. Conclusions The anti-inflammatory and moisturizing effects of potassium azeloyl diglycinate combined with the protective properties of HPCH allow the new product to be a good candidate for controlling signs and symptoms of rosacea.
Disciplines :
Dermatology
Author, co-author :
Berardesca, Enzo; San Gallicano Dermatological Institute > Dermatology
Iorizzo, Matilde
Abril, Elva
Guglielmini, Giancarlo
Caserini, Maurizio
Palmieri, Renata
PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Language :
English
Title :
Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.
Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006; 78: 97-100.
Culp B, Scheinfeld N. Rosacea: a Review. Pharm Ther 2009; 34: 38-45.
Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41.
Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res 2005; 10: 454-6.
Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.
Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H 2O 2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1996; 271: 21793-7.
Piérard-Franchimont C, Quatresooz P, Piérard GE. Incidental control of rosacea by somatostatin. Dermatology 2003; 206: 249-51.
Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
Sparavigna A, Setaro M, Frisenda L. Physical and microbiological properties of a new nail protective medical device. J Plastic Dermatol 2008; 4: 1.
Monti D, Saccomani L, Chetoni P et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005; 31: 11-17.
Berardesca E, Borroni G. Instrumental evaluation of cutaneous hydration. Clin Dermatol 1995; 13: 323-7.
Piérard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998; 10: 1-11.
Berardesca E, Cameli N, Cavallotti C et al. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol 2008; 7: 8-14.
Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4: S19-22.